{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:45:13Z","timestamp":1793144713657,"version":"4.5.0"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0169401","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T22:30:36Z","timestamp":1484001036000},"page":"e0169401","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir\/Ledipasvir in Germany"],"prefix":"10.1371","volume":"12","author":[{"given":"Jona T.","family":"Stahmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegbert","family":"Rossol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Liersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,1,3]]},"reference":[{"key":"ref1","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva; 2014."},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"JF Perz","year":"2006","journal-title":"J Hepatol"},{"issue":"5\u20136","key":"ref3","first-page":"707","article-title":"Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)","volume":"56","author":"C Poethko-Muller","year":"2013","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"Suppl 1","key":"ref4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jvh.12247","article-title":"Historical epidemiology of hepatitis C virus (HCV) in selected countries","volume":"21","author":"P Bruggmann","year":"2014","journal-title":"J Viral Hepat"},{"issue":"1","key":"ref5","first-page":"34","article-title":"Epidemiology of chronic hepatitis C in Germany\u2014an analysis of 10,326 patients in hepatitis centres and outpatient units","volume":"46","author":"D Huppe","year":"2008","journal-title":"Z Gastroenterol"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"JM Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/apt.13081","article-title":"Cost-effectiveness of all-oral ledipasvir\/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection","volume":"41","author":"ZM Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/M14-1336","article-title":"Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States","volume":"162","author":"J Chhatwal","year":"2015","journal-title":"Ann Intern Med"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","article-title":"Cost-effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","author":"M Najafzadeh","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12876-015-0320-4","article-title":"Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US","volume":"15","author":"S Zhang","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"ref11","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden zur Bewertung von Verh\u00e4ltnissen zwischen Nutzen und Kosten. Cologne: 2009."},{"key":"ref12","first-page":"12","article-title":"Das Deutsche Hepatitis C-Register: erste Daten","volume":"9","author":"D H\u00fcppe","year":"2015","journal-title":"HepNet Journal"},{"issue":"20","key":"ref13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"ref14","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"ref15","unstructured":"European Medicines Agency. Harvoni\u2014Summary of Product Characteristics. 4-12-2014."},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJMc1307641","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"369","author":"E Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"ref17","unstructured":"European Medicines Agency. Sovaldi\u2014Summary of Product Characteristics. 2014."},{"issue":"21","key":"ref18","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"P Ferenci","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"ref19","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"JJ Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"ref20","unstructured":"European Medicines Agency. Exviera\u2014Summary of Product Characteristics. 2016."},{"issue":"9941","key":"ref21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"IM Jacobson","year":"2014","journal-title":"Lancet"},{"issue":"9941","key":"ref22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"M Manns","year":"2014","journal-title":"Lancet"},{"key":"ref23","unstructured":"European Medicines Agency. Olysio\u2014Summary of Product Characteristics. 2014."},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"ref25","unstructured":"European Medicines Agency. Daklinza\u2014Summary of Product Characteristics. 2014."},{"issue":"9956","key":"ref26","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"E Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"25","key":"ref27","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"ref28","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"JG McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"ref30","unstructured":"Bourliere M, Sulkowski M, Omata M, Zeuzem S, Feld J, Lawitz E, et al. An Integrated Safety and Efficacy Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir\/Sofosbuvir With or Without Ribavirin, AASLD 2014. 2014."},{"issue":"16","key":"ref31","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref32","unstructured":"US Department of Veterans Affairs. FDA Approval for Sofosbuvir. 2014. 14-4-2016."},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"P Andreone","year":"2014","journal-title":"Gastroenterology"},{"issue":"17","key":"ref34","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"ref35","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"X Forns","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"146","author":"S Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"issue":"25","key":"ref37","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"S Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"ref38","unstructured":"European Medicines Agency. Incivo\u2014Summary of Product Characteristics. 2014."},{"key":"ref39","unstructured":"European Medicines Agency. Victrelis\u2014Summary of Product Characteristics. 2014."},{"issue":"13","key":"ref40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"BR Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"ref41","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"F Poordad","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S0266462309090229","article-title":"Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice","volume":"25","author":"M Grishchenko","year":"2009","journal-title":"Int J Technol Assess Health Care"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"AC Cardoso","year":"2010","journal-title":"J Hepatol"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"G Fattovich","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10198-005-0280-7","article-title":"Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany","volume":"6","author":"U Siebert","year":"2005","journal-title":"Eur J Health Econ"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11110","article-title":"Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation","volume":"11","author":"J Shepherd","year":"2007","journal-title":"Health Technol Assess"},{"key":"ref47","unstructured":"Federal Statistical Office. Periodensterbetafeln f\u00fcr Deutschland. Wiesbaden: 2012."},{"key":"ref48","unstructured":"Siebert U, Ravens-Sieberer U, Greiner W, Sroczynski G, Wong JB, Kuntz KM, et al. Performance of different utility assessment methods in chronic hepatitis C patients. In: Kind P, Macran S, editors. Proceedings of the 19th Plenary Meeting of the EuroQol Group 13th-14th September 2002 Discussion Papers.York: UK Centre for Health Economics; 2003. p. 175\u201384."},{"issue":"2","key":"ref49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/apt.12354","article-title":"Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study","volume":"38","author":"M Vera-Llonch","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref50","unstructured":"NICE. Telaprevir for the treatment of genotype 1 chronic hepatitis C. 2012."},{"key":"ref51","unstructured":"NICE. Boceprevir for the treatment of genotype 1 chronic hepatitis C. 2012."},{"key":"ref52","unstructured":"LAUER-FISCHER GmbH. Lauer-Taxe Online\/German Drug Directory. 2016."},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.52.3.425","article-title":"Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"52","author":"U Siebert","year":"2003","journal-title":"Gut"},{"issue":"3","key":"ref54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.36469\/9870","article-title":"Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany","volume":"1","author":"JT Stahmeyer","year":"2013","journal-title":"Journal of Health Economics and Outcomes Research"},{"issue":"9","key":"ref55","first-page":"1041","article-title":"Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany","volume":"52","author":"JT Stahmeyer","year":"2014","journal-title":"Z Gastroenterol"},{"issue":"1","key":"ref56","first-page":"57","article-title":"Health economics of chronic infectious diseases: the example of hepatitis C","volume":"49","author":"J Wasem","year":"2006","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"4","key":"ref57","first-page":"320","article-title":"S3 guideline hepatitis C addendum","volume":"53","author":"C Sarrazin","year":"2015","journal-title":"Z Gastroenterol"},{"issue":"4","key":"ref58","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report","volume":"12","author":"M Drummond","year":"2009","journal-title":"Value Health"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12546","article-title":"Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort","volume":"39","author":"LI Backus","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Curry MP, Bacon B, Dieterich D, Flamm SL, Guest L, Kowdley KV, et al. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Na\u00efve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. AASLD 2015. 2015.","DOI":"10.1016\/j.jval.2016.03.992"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Curry MP, Bacon B, Dieterich D, Flamm SL, Guest L, Kowdley KV, et al. Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-world Experience from the TRIO Network. AASLD 2015. 2015.","DOI":"10.1016\/j.jval.2016.03.991"},{"key":"ref62","unstructured":"Mauss S, Schewe K, Rockstroh JK, Hueppe D, Baumgarten A, Schmutz G, et al. Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1and 4 in clinical practice\u2014Results from the GErman hepatitis C COhort (GECCO). AASLD 2015. 2015."},{"issue":"27","key":"ref63","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMe1513245","article-title":"Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs","volume":"373","author":"JW Ward","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"ref64","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/cer.15.13","article-title":"Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals","volume":"4","author":"JT Stahmeyer","year":"2015","journal-title":"J Comp Eff Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0169401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T19:36:25Z","timestamp":1601321785000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0169401"}},"subtitle":[],"editor":[{"given":"Ferruccio","family":"Bonino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,3]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0169401","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,3]]}}}